Press release: Landmark global initiative sets out roadmap for equitable precision oncology
A commission report on precision medicine in cancer was published in "Lancet Oncology" on September 25. Kjetil Taskén is the only Norwegian author involved in this work, and OUS is listed as a contributing institution. Convening expertise in oncology, genomics, pathology, public health, health policy, economics, data science, ethics and patient advocacy, the Commission is the most comprehensive evaluation of precision oncology ever undertaken.
In conjunction with this project, Taskén was invited to write a review article on the status of cancer genomics and precision oncology in Europe. He led this work, together with Live Fagereng from OUS (first author), alongside 25 other principal authors from various European countries and 159 consortium authors - a broad collaboration designed to capture the full scope of the initiative across Europe. The resulting article was published in "The Lancet Regional Health – Europe" simultaneously with the "Lancet Oncology" report.
This European status overview is one of several papers being released alongside the commision report; the aim is to provide a comprehensive worldwide picture of the situation. The publication is scheduled to coincide with the UICC World Cancer Congress in Hong Kong on September 25, aligning with the release of the Lancet Oncology report and other Lancet journal publications.
Press releases:
On the commission report on precision medicine in cancer, published in The Lancet Oncology:
Landmark global initiative sets out roadmap for equitable precision oncology
On the review article on the status of cancer genomics and precision oncology in Europe, published in The Lancet Regional Health – Europe:
Precision oncology in Europe: real progress, uneven access, and a roadmap to equity
The articles:
Casolino, R. Mateo, J., de Vries, E., Johns, A., Courtot , M., Lawlor , R.T., Perdomo, S., Gray, S.W., Lopez, R.P. Turnbull, C., Torrents, D., Vokinger, K.N., Akhoundova, D., Bourque, J.-M., Cardona, A.F., Chakravarty, D., Chicherova, I., Cranston, K.A., Davis, M., Frisell, O. Garcia, R.M., Grossman, R.L., Hamdi, Y., Hediger, S., Hofmarcher, T., Hofmann, O., Kather, J.N., Kato, K., Knoppers, B.M., Lehmann, K.-V., Lokuhetty, D., Mascalzoni, D., Mulder, N., Osterman, T., Parikh, A.R., Rotimi, S., Rous, B., Sirohi, B., Sondka, Z., Staunton, C., Taskén, K., Wagner, A., Westphalen, C.B., Wu, J., Yann, J., Zawati, M.,H., Biankin, A.V., Yoshino, T., Stein, L., Lawler, M. (2026)
Accelerating Equitable Cancer Genomics and Precision Oncology in Health Care and Research: A Lancet Oncology Commission.
The Lancet Oncology
Fagereng, G.L., Abel, E., CAN.HEAL Consortium, Casolino, R., De Maria, R., Fröhling, S., Gelderblom, H., Hernando-Calvo, A., Hill, S., JA PCM Consortium, Jalkanen, K., Kamal, M., Krebs, M.G., Lawler, M., le Tourneau, C., Lepland, A., Ługowska, I., Mainoli, B., Normanno, N., Obermannova, R.L., Piris-Giménez, A., PRIME-ROSE and PCM4EU Consortium, Rohrberg, K.S., Ryll, B., van den Bulcke, M. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Van Valckenborgh, E., Verlingue, L., Westphalen, C.B., Taskén, K.* (2026)
Landscape of cancer genomics and precision oncology in Europe.
Lancet Regional Health - Europe
(*corresponding author and with 159 consortium authors in CAN.HEAL, JA PCM and PRIME-ROSE &PCM4EU Consortia)
Links:
Kjetil Taskén, leader of the Cell Signalling and Immune Regulation group and head of the Institute for Cancer Research
PRIME-ROSE - Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials-
JA PCM - The European Joint Action on Personalised Cancer Medicine